Covid-19 vaccine in India : Status of emergency use authorisation (EUA)
Published On: Wednesday, December 9, 2020 | By: Team KnowMyStock
Bharat Biotech International (BBIL) had changed the dosage from 3 micrograms of antigen to 6 micrograms during its Covid-19 vaccine trial, a point that the subject expert committee (SEC) would closely examine when it meets on 9th December 2020 to review its application for an emergency use authorisation (EUA) for Covaxin. The panel would also review the applications of Pfizer-BioNTech and Serum Institute of India (SII) seeking a EUA for their vaccines. While many have raised questions over BBIL applying for a EUA during an ongoing efficacy trial, the Indian Council of Medical Research (ICMR), the country’s apex health research institute, has defended the move.
ICMR Director General Balram Bhargava said that in the case of temporary licensure or emergency use, the regulator had to be satisfied with the risk-benefit ratio. “In this emergency situation, if the benefit is more, then it may be considered.” At least two experts working closely with the regulator on this process said that in a risk-benefit analysis during a pandemic, one had to first look at the safety parameters of the candidate, and then evaluate its efficacy.
We are on Telegram!
JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.
Click Here!
Follow Us On:
